Platinum-based chemotherapy is the first-line treatment for non-small cell lung cancer, but recurrence occurs in most patients. Recent evidence suggests that CD133+ cells are the cause of drug resistance and tumor recurrence. However, the correlation between chemotherapy and regulation of CD133+ cells has not been investigated methodically. In this study, we revealed that CD133+ lung cancer cells labeled by a human CD133 promoter-driven GFP reporter exhibited drug resistance and stem cell 
Introduction
Non-small cell lung cancer (NSCLC) represents approximately 80% of all lung cancers, and platinum-based chemotherapy is the standard first-line therapeutic approach to treat patients with NSCLC. However, the patients treated with single modalities are at a high risk for local regional recurrence and distant relapse (1) . Over the past few decades, trials have evaluated the benefits of doublet chemotherapy by combination of cisplatin with other non-platinum drugs. Although the overall median survival of the patients who received platinum-based therapy has reached 9-12 months (2), the chemoresistance of tumor cells continues to be a considerable challenge in the management of NSCLC. Tumor cells often show initial sensitivity to chemotherapeutic drugs, but acquired resistance develops during the treatment, leading to tumor recurrence and further tumor progression. The most cited mechanism for the acquisition of drug resistance is the active efflux of chemotherapeutic agents via ATP-binding cassette (ABC) transporters, such as P-glycoprotein Pgp/MDR1/ABCB1, breast cancer resistance protein BCRP/ABCG2, and multi-drug resistance proteins (MRPs) (3) . However, there is no effective treatment strategy to override these transporters for clinical therapy. In addition, several receptor-mediated survival signaling pathways, including mitogen-activated protein kinase (MAPK), Akt, mTOR, NF-κB and Notch pathways, have been linked to the drug resistance of conventional chemotherapy (4) (5) (6) . A recent study showed that expression of CD133 is associated with the levels of resistance-related proteins in NSCLC patients (7) .
Furthermore, a combination of CD133 and ABCG2 can be used as an independent predictor of postoperative recurrence for patients with stage I NSCLC (8) . The mechanisms causing drug resistance in CSCs are still poorly understood; CSCs may be intrinsically resistant to chemotherapeutic agents due to their low proliferation rate and resistance mechanisms, such as the expression of ABC transporters (9) .
Even though the origin of CSCs is unknown, there is a consensus that CSCs reside in a niche that provides the cells with elementary signals. Notch signaling is critical for regulating cell-to-cell communication during embryogenesis, cellular proliferation, differentiation, and apoptosis (10) . Activation of Notch signaling occurs when the Notch receptor undergoes a conformational change that allows proteolytic cleavage by γ-secretase, releasing an intracellular domain (NICD) that undergoes nuclear translocation and modulates Notch-specific gene expression. Recently, inhibition of γ-secretase-mediated Notch cleavage is a primary focus for the development of cancer therapeutics (11) . Targeting CSCs with inhibitors of Notch signaling promotes cell differentiation, increases sensitivity to chemotherapy, and reduces metastasis (12) .
Although the drug action of cisplatin has been widely explored (13) , whether cisplatin may regulate the ratio of CSCs and elicit further multi-drug resistance in NSCLC is still unknown. Here, we provide evidence showing that cisplatin treatment significantly increased the ratio of CD133+ cells through the Notch signaling pathway.
The cisplatin-elevated CD133+ cells were resistant to paclitaxel and doxorubicin by expressing ABCB1 and ABCG2. In addition, the enrichment of CD133+ cells by cisplatin was demonstrated in a tumor-engrafted mouse model and clinical specimens. 
Materials and Methods

Clinical Specimens
We enrolled 6 lung cancer patients diagnosed from 2010 through 2012 with adenocarcinoma or squamus cell carcinoma from Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) with approval of Institutional Review Board (KMUH-IRB-20120068). These patients received combination chemotherapy of cisplatin with docetaxel, gemcitabine, vinorelbin, or pemetrexed for 4-6 cycles according to the guideline of KMUH. The initial response of these patients for the first-line chemotherapy was from partial response to stable disease, which tumor recurrence occurred within one year. All these patients received surgery or thoracoscopic biopsy for the relapsed tumor. The primary (before cisplatin treatment) and relapsed (after cisplatin treatment) tumors of each patient were paraffinembedded, sectioned and used for evaluating CD133+ cells by immunohistochemistry.
Immunohistochemistry (IHC)
Tissue sections (5 μm) were dewaxed and rehydrated. Antigen retrieval was done by incubating the slides in 10 mM citric buffer (pH6.0) and microwaved for 15 min. After blocking, the slides were incubated with primary antibody against CD133 followed by biotin-conjugated secondary antibody, polymer-HRP and diaminobenzidine tetrahydroxychloride (DAB) solution.
Cell culture
The human NSCLC cell lines A549, H460, H1299, PC9 and H661 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).
A549, H1299 and PC9 cell lines were maintained in Dulbecco's Modified Eagle 
Generation of plasmids and lentivirus preparation
The shRNAs targeting ABCB1 and Notch1 were purchased from Invitrogen.
The EF.hICN1.CMV.GFP plasmid was a gift from Dr. Linzhao Cheng (Addgene plasmid #17623). For generation of the human CD133 promoter construct (CD133-GFP reporter), chromosomal DNA was isolated from HEK293T cells. the 5'-promoter P1 region of the human prominin1 gene (CD133; GenBank accession number AY275524) was generated by PCR amplification cloned into lentiviral vector pLL3.7 to replace the CMV promoter, which drives EGFP expression. 
Isolation of CD133+ cells and sphere-forming assay
Quantitative real-time PCR (Q-PCR)
Total RNA isolation and reverse transcription were performed using the method as described previously (14) . The mRNA expression of CD133, Oct4, β-catenin, Bmi- 
Western blot
For Western blot analysis, cells were harvested and lysed in 1X RIPA buffer containing protease inhibitor cocktails (Roche, Mannheim, Germany). The detail protocol for Western blot and the antibodies used in this study were described in Supplementary Materials and Methods.
Soft agar assay
A soft-agar assay was performed on 6-well plates with a base layer of 0. 
Immunofluorescence assay
After the tumors were removed from xenografted mice, half of each tumor was fixed in 4% formalin at 4°C overnight. The immunofluorescence was performed using anti-CD133 antibody and anti-cleaved Notch1 antibody.
Statistical analysis
Data are presented as the mean±SE. To analyze the triplicate results of the experiments, two-tail Student's t-test was used to demonstrate significant differences.
Additional information was described in Supplementary Materials and Methods. 
Results
CD133+ cells isolated from the H460 cell line display the characteristics of cancer stem cells.
Studies have shown that CD133+ cells in different lung cancer cell lines exhibit self-renewal and tumor-initiating abilities. To isolate CD133-expressing cells, we constructed a human CD133 P1 promoter-driven GFP reporter into the PLL3.7 lentiviral vector (Fig. 1A ). After infection, 1.5±0.5% GFP+ cells were identified in the H460 cell line ( Supplementary Fig. S1A ). The GFP+ cells were sorted and cultured in ultra-low adhesion culture dishes containing stem-cell medium, which allowed the cells to grow as tumor spheres and maintain GFP expression ( and subjected to Q-PCR analysis. The results showed that the expression of stemnessassociated genes in differentiated GFP+ cells was significantly decreased when compared with undifferentiated GFP+ cells (Fig. 1J) . Our data confirmed the existence of CD133+ cells in the H460 cell line with a CD133 antibody and hCD133 promoter-driven GFP reporter lentivirus. The CD133+ cells were also characterized as CSCs.
Cisplatin treatment elevates the ratio of CD133+ cell
To study whether cisplatin may elevate the ratio of CSCs in lung cancer, we first tested the cytotoxic effect of cisplatin in NSCLC cell lines. Two lung cancer cell lines, H460 and H661, were treated with different concentrations of cisplatin for 24h and 48h, and cell viability was determined by MTT assay (Fig. 2A) . Cisplatin-induced DNA damage was confirmed by the activation of DNA damage sensors, including cleaved PARP and phospho-γH2AX as well as the transducer phospho-CHK1, which leads to the elevation of p53 expression (Fig. 2B) . According to the results from the cytotoxic analysis of cisplatin, H460 and H661 cells were treated with 10 μM and 2  μM cisplatin for 24h, respectively, which are sufficient to induce DNA damage but not significant cell death (~IC 20 Fig. S2A and S2B ). In addition to H460 and H661, this phenomenon could be observed in another cell lines, including H1299, A549 and PC9 ( Supplementary Fig. S2C ). In addition to cisplatin, carboplatin is also used as a platinum-base chemotherapy agent for NSCLC, especially for the patients with chronic renal diseases. We found that carboplatin Fig. S3 ).
Aldehyde dehydrogenase (ALDH) has been reported as another lung cancer stem cell marker (15), and we found that cisplatin treatment also increased the ratio of ALDH+ cells in H460 cell cultures (Supplementary Fig. S4 ). As expected, the stem cell-associated genes CD133, Oct4, Sox2, Nanog, and Notch1 and the multi-drugresistant genes ABCG2 and ABCB1 were up-regulated in cisplatin-primed H460 and H661 cultures (Fig. 2D ). Next, we tested whether cisplatin treatment could increase the ratio of the cells with stem cell properties. After cisplatin treatment for 24h, the remaining cells were subjected to the tumor-sphere and soft-agar colony forming assays. Compared with vehicle controls, the cisplatin-treated cells generated more tumor spheres (Fig. 2E ) and colonies in soft-agar cultures (Fig. 2F) . Next, to demonstrate whether the increase of stem cell-associated genes was specifically expressed in CD133+ cells, CD133-and CD133+ cells were sorted from the cisplatintreated H460 cell line. The purity of the sorted cells was confirmed by flow cytometry and Western blot (Fig. 2G) . Results from Q-PCR showed that the stem cell-associated genes were highly expressed in the CD133+ cells, while the CD133-cells showed a similar expression pattern with the parental cells (Fig. 2H) . Collectively, these results indicated that cisplatin elevated the ratio of CD133+ cells, which displayed stem cell properties.
Cisplatin-induced CD133+ cells display multi-drug resistance
ABCB1 and ABCG2 mediate the drug resistance of cancers for a range of chemotherapy drugs, including paclitaxel and doxorubicin (16) . In our results, cisplatin-induced CD133+ cells expressed higher levels of ABCB1 and ABCG2 mRNA ( Fig. 2D and 2H) . Thus, we hypothesized that the cisplatin-induced 
enrichment of CSCs may display multi-drug resistance. By treating with doxorubicin at different concentrations for 48h, the vehicle control in H460 cells had an IC 50 of 90.9±8.2 nM, but cisplatin-treated cells showed an IC 50 of >500 nM (Fig. 3A) . In addition to doxorubicin, cisplatin-primed cells also exhibited drug resistance to paclitaxel treatment (Supplementary Fig. S5A ). Pretreatment with 5 μM pantoprazol, a specific inhibitor for ABCG2, significantly blocked cisplatin-induced protection to doxorubicin treatment in H460 cells (Fig. 3B) . On the other hand, pretreatment with 5 μM verapamil, a pan-inhibitor for ABC transporters, completely inhibited cisplatininduced doxorubicin resistance of H460 cells (Fig. 3C) . These results suggested that cisplatin-induced ABCG2, but not ABCB1, expression in CD133+-enriched cultures leads to drug resistance to doxorubicin treatment. This conclusion was further confirmed by the observation that ABCB1 knockdown by specific shRNAs (Fig. 3D) did not reverse the cisplatin-induced doxorubicin resistance (Fig. 3E) . In contrast to the role of ABCG2 in doxorubicin resistance, pantoprazol partially reversed cisplatininduced drug resistance to paclitaxel, but varapamil completely inhibited the effect of cisplatin on H460 and H661 cells, suggesting that not only ABCG2 but also other ABC transporters may be involved in cisplatin-induced multi-drug resistance (Supplementary Fig. S5B and S5C) . Interestingly, although doxorubicin alone at IC 20 concentration was sufficient to induced DNA damage, but little effect was observed on CD133+ cell enrichment (Fig. 3F) . In addition, co-treatment of cisplatin and doxorubicin did not have an additional effect on regulating the ratio of CD133+ cell in the H460 culture, suggesting that the induction of CD133+ cells was mediated by the mechanisms specifically triggered by cisplatin but not by doxorubicin. On the other hand, cisplatin combined with paclitaxel is one of the currently therapies for NSCLC. However, paclitaxel alone or co-treatment of cisplatin and paclitaxel had no CAN-12-1733 further induction effect on the enrichment of CD133+ cells (Supplementary Fig.   S5D ). Collectively, we concluded that cisplatin treatment induced DNA damage and triggered CD133+ cell enrichment.
Cisplatin-induced enrichment of CD133+ cells is mediated by Notch1 signaling
A number of studies have demonstrated that activation of Notch signaling maintains stemness and the self-renewal ability of normal stem cells and CSCs (15, 17) . Inhibition of Notch signaling promotes differentiation of CSCs (18) . Although cisplatin-induced Notch1 expression and activation have been discussed in some cancer types (19) , studies on the correlation between cisplatin and Notch signaling in lung cancer are lacking. Thus, we were interested in investigating whether the increase of CD133+ cells by cisplatin treatment is mediated by Notch signaling in lung cancer cells. As shown in Fig. 4A , treatment of cisplatin dose-dependently increased Notch1 cleavage and activated it downstream target gene, Hes-1 (Fig. 4C ).
In contrast, the level of cleaved Notch3 was not altered by cisplatin treatment, suggesting that Notch1 activation may play a major role on cisplatin-induced enrichment of CD133+ cells (Supplementary Fig. S6A ). Pretreatment with γ-secretase inhibitor, DAPT, abolished cisplatin-induced Notch1 activation (Fig. 4B) as well as the mRNA expression of Hes-1 (Fig. 4C) . DAPT only did not alter the ratio of CD133+ cells in the H460 and H661 cell lines as compared with the control.
However, pretreatment of DAPT significantly inhibited cisplatin-induced enrichment of CD133+ cells in H460 (Fig. 4D ) and H661 cells (Supplementary Fig. S7A ). On the other hand, shRNAs specifically targeting Notch1 greatly blocked cisplatin-induced enrichment of CD133+ cells ( Supplementary Fig. S6B and S6C ). (Fig. 4E) . This DAPT-induced blockage of paclitaxel resistance could also be observed in H661 cells (Supplementary Fig. S7 ). To confirm the importance of Notch1-mediated signaling in cisplatin-induced multi-drug resistance, we transiently transfected the human Notch1 intracellular domain construct (hICN1) into H460 cells (Fig. 4F) . Ectopically expressed hNICD1 did not change the cytotoxicity of paclitaxel in H460 cells (Fig. 4G) . However, the blockage of cisplatin-induced paclitaxel resistance by DAPT was greatly reversed by ectopically expressed hNICD1 (Fig. 4G ).
Cisplatin treatment increases the ratio of CD133+ cells in lung tumor of patients and in H460-xenografted nude mice
Accumulating evidences have demonstrated a tumor re-growth cell hierarchy originating with the survived CSCs after chemotherapy. According to the results from our in vitro study, we assumed that CD133+ cells might increase in relapse tumors of the patients who received cisplatin as their first chemotherapy. We enrolled 6 lung cancer patients with resected tumor (before) and who received cisplatin as their first chemotherapy. All these patients experienced tumor recurrence and received surgery or endoscopy for the relapsed tumors (after). Tumor samples, before and after cisplatin treatment, were paraffin-embedded and sectioned. The expression of CD133 was examined by immunohistochemistry. As shown in Fig. 5A , CD133 staining signal can be detected in the tumor region but not in the surrounding normal tissue. Accumulating evidence has demonstrated that CSCs may not only originate from the transformation of normal stem cells but also arise from the de-differentiation of cancer cells (22) . An impressive observation has shown that CSCs exist in single cancer cell-derived cultures, which reveals the flexibility of the cancer cell status in tumors due to genomic instability in cancer cells (23, 24) . In addition, the dedifferentiation of cancer cells can be induced by different environmental cues, such as inflammation, hypoxia, and serum deprivation through epigenetic or genetic regulation (25) . Recently, epithelial-to-mesenchymal transition (EMT) has been broadly demonstrated to convert mature cancer cells into CSCs (26, 27) , which is mediated by EMT-associated genes and microRNAs (28) (29) (30) . In our study, we demonstrated that treatment with cisplatin elevated CD133+ cells in the H460 and H661 cell lines. This induction effect could not be resulted from eliminating CD133-cells, which is more sensitive to cisplatin, and preserving the existing CD133+ cells before treatment because limited cells were killed by a low dose of cisplatin around the IC 20 for each cell line during treatment. On the other hand, a high-dose treatment (>IC 50 ) of paclitaxel, which induced significant cell death, showed no effect on 
regulating CD133+ cell number in the H460 and H661 cell lines. These results indicated that cisplatin might induce de-differentiation of NSCLC cells.
Cancer cells are considered to be more genetically unstable, which can be accelerated by exogenous and endogenous exposures that cause DNA damage, such as irradiation and chemotherapy (31) . A previous study showed that DNA damage induced by UV light and mitomycin C increased the side population in human nasopharyngeal carcinoma and CD133+ cells in human neuroblastoma SKN-SH cells (24) . In our study, we demonstrated that cisplatin-induced DNA damage could be another driving force that triggers the enrichment of H460 and H661 cells. Notch1 is important for the maintenance and self-renewal of cancer-initiating cells in different malignancies (15, 36, 37) . Inhibition of Notch signaling promotes differentiation and the radio-and chemotherapy of CSCs (38) . In contrast, overexpression of Notch1 promotes EMT and the number of CSCs in pancreatic cancer. We found that inhibition of Notch signaling by pretreatment with the γ- I NSCLC (44) . In vitro study showed that ABCG2-overexpressing human NSCLC cell lines were more resistant to chemotherapy (45, 46) . Inhibition of ABCG2 and/or ABCB1 by selective inhibitors sensitized NSCLC cells to chemotherapy (47, 48) . 
